Molecular Partners to present initial Phase 1/2a data on MP0712 in lung cancer, other solid tumors
MOLN•Molecular Partners will present initial Phase 1/2a dose-escalation results for MP0712 on December 5, 2026. The first-in-human trial evaluates the candidate in small cell lung cancer and other DLL3-expressing solid tumors.
1. Upcoming presentations
Molecular Partners will present initial MP0712 Phase 1/2a dose-escalation results at the North America Conference on Lung Cancer on December 5, 2026. The first-in-human trial evaluates the candidate, co-developed with Orano Med, in small cell lung cancer and other DLL3-expressing solid tumors; a November 7 presentation at the 2026 SNMMI Theranostics Conference will cover lessons from advancing MP0712 into clinical testing.
